Hall talks about increase in federal investigations for drug and medical device companies

Hall talks about increase in federal investigations for drug and medical device companies

"SEC disclosures show that off-label, antikickback, Best Price cases continue to dominate enforcement landscape", RX Compliance Report

May 21, 2009

Christopher R. Hall, Partner in the Litigation Department and Corporate Governance Practice Group, served as the main source for this article about how drug and medical device companies are the targets of increased state and federal government scrutiny. According to a review conducted by Saul Ewing LLP, there are more than 50 active investigations underway at U.S. Attorneys' Offices around the country involving drug and medical device companies. The data was collected to help drug and device companies develop annual risk assessments.

View Document(s):